Company news
uniQure N.V. news in 2020
uniQure N.V.'s news releases, calls and decks from 2020, newest first.
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
December 20, 2020
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
December 7, 2020
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
December 6, 2020
uniQure to Participate in Multiple Upcoming Industry Conferences in December
December 1, 2020
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
November 29, 2020
uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
November 18, 2020
uniQure to Participate in Multiple Upcoming Industry Conferences in November
November 3, 2020
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
October 26, 2020
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
October 12, 2020
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
September 24, 2020
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
August 25, 2020
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
July 29, 2020